Characterization of PDA NP size, zeta potential and morphology
As mentioned, PDA NPs were synthesized through DA oxidative polymerization in an alkaline medium containing EtOH in the presence of atmospheric oxygen35,36. Generally, most authors let this polymerization reaction take place for 24 h. Nevertheless, it has found that it is possible to obtain PDA NPs with the same physicochemical properties after 3 h in previous work25, and the reaction was only allowed to pass this time. Herein, PDA NP hydrodynamic diameter after 3 h of reaction was 172.7 ± 53.6 nm (PDI: 0.074), while their zeta potential was − 39.9 mV at pH 10.0, -17.4 mV at pH 7.4, and − 7.1 mV at pH 4.5. These last values were like other previously reported, and indicated that PDA nanocolloids had minor stability in acidic environments25.
After loading PDA NPs with the different drugs and with the mAb, both their size and surface charge changed, as can be seen in Fig. 1A-B. On one hand, NP diameter increased after all loading processes. In this manner, PDA NPs reached 210.4 ± 72.9 nm (PDI: 0.130) after 5FU loading (3.9 µg/mg), while their diameter increased up to 216.6 ± 80.9 nm (PDI: 0.116) after CPT11 loading (17 µg/mg). Likewise, once LV was incorporated into PDA NPs (32 ug/mg), their diameter turned out to be 205.3 ± 67.7 nm (PDI: 0.101), therefore being this increase somewhat less remarkable than in the previous cases. Otherwise, when 5FU, CPT11 and LV were all loaded together in PDA NPs, their hydrodynamic diameter increased to 231.6 ± 81.9 nm (PDI: 0.139). Moreover, interestingly, while the incorporation efficiency (IE) of LV was like that obtained after individual adsorption of the drugs (29 µg/mg), 5FU and CPT11 IEs were higher (4.9 µg/mg and 18.4 µg/mg, respectively) when the three drugs were adsorbed together, which may indicate that there was not significant competition for PDA binding sites among 5FU, CPT11, and LV. Besides, when PDA NPs were loaded with all the FOLFIRI compounds and CTX, their diameter augmented even further, reaching 297.3 ± 102.3 nm (PDI: 0.193). Since the increase was quite large, it was also decided to determine the size of the NPs loaded only with the mAb, finding that it was about 258.8 ± 97.7 nm (PDI: 0.100). Consequently, CTX incorporation significantly modified PDA NP diameter. In addition, 5FU and LV IEs were remarkably reduced (to 1.7 µg/mg and 3 µg/mg, respectively) after the incorporation of the mAb into the nanosystem, which was also lower than when CTX was adsorbed in isolation (3.2 µg/mg vs. 5.2 µg/mg). The only IE that did not decrease much after CTX loading was that of CPT11 (18.4 µg/mg). To facilitate the comprehension of the work, the IEs obtained after all adsorption processes, expressed both in ug/mg and in percentage, are collected in Table S1.
(A) DLS intensity distributions of the different PDA NPs dispersions in Trizma buffer (pH 10.0, 50 mM; (B) Hydrodynamic diameter (nm) of PDA NPs before and after loading them with the different drugs and the antibody specified under each bar; (C) Zeta potential values of the different PDA-based nanosystems, as well as of free 5FU, CPT11 and LV, at pH 4.5, 7.4, and 10.0.
On the other hand, PDA NP zeta potential became more negative after the loading of three drugs, either individually or in isolation, both at pH 7.4 and 4.5. This behavior, which can be seen in Fig. 1C, could be indicative that drugs were being internalized into PDA NP structure, as also shown by the SEM images that were taken (Fig. 2). In these images, morphology of bare PDA NPs (Fig. 2A) and of those loaded with 5FU, CPT11, and LV (Fig. 2B-E) did not differ significantly despite the increase in the size of the latter. However, when CTX was adsorbed, NP zeta potential notably acquired more positive values, regardless of whether they were previously conjugated with FOLFIRI drugs. This fact, which had already been reported by El Hallal et al.37, could show that the mAb was retained on PDA NP surface. Besides, this fact would explain why the size of CTX@PDA NPs and FOLFIRI-CTX@PDA NPs increased so much after the incorporation of the antibody, and why their morphology differed somewhat more from that of the rest of the PDA nanosystems (Fig. 2F).
SEM images and size histograms of all PDA nanosystems: (A) PDA NPs, (B) 5FU@PDA NPs, (C) CPT11@PDA NPS, (D) LV@PDA NPs, (E) FOLFIRI@PDA NPs and (F) FOLFIRI-CTX@PDA NPs.
Drug-loading characterization by FT-IR
With the aim of assessing 5FU, CPT11, and LV incorporation into PDA NPs, FT-IR assays were performed to compare the spectra of PDA NPs, 5FU, CPT11, LV, 5FU@PDA NPs, CPT11@PDA NPs, and LV@PDA NPs.
Starting with 5FU loading, some of the bands existing in 5FU spectrum could also be observed in that of 5FU@PDA NPs (Fig. 3A). Some of them were, for instance, the intensity band at 420 cm− 1 corresponding to bending of the halogen bond within the ring of the aromatic fluorinated compound; the absorption band at 550 cm− 1 that could be attributed to C-F deformations31; and the absorption bands observed at 752 and 870 cm− 1, which may correspond to C–H out of the plane vibrations at –CF = CH–38. Likewise, the absorption band at 1180 cm− 1, which could be assigned to C-O vibrations31; the absorption band at 1429 cm− 1 that could be assigned to C-N stretching vibrations39; the absorption band at 1580 cm− 1 that may correspond to C-N and C-C ring stretching vibrations; the adsorption band at 1723 cm− 1 that could be related to C = O stretching frequency; and the adsorption band at 2930 cm− 1 that may be attributed to the -CH2 group could be differentiated in both spectra31, so 5FU loading was successfully performed.
Secondly and regarding the absorption of CPT11, it was also observed that some characteristic bands of this drug existed in CPT11@PDA NPs, so its loading was successful, too (Fig. 3B). Some of these bands were, for example, those at 1160 cm− 1 and 1230 cm− 1, which may correspond to the stretching vibration of the C–O ester and to the C = C and C–CH3 aromatic stretching vibrations, respectively; and those bands at 1660 and 1745 cm− 1, which may be assigned to the C = O group from the lactone, the carbamate, and the pyridine group40.
Finally, it could also be seen that LV and LV@PDA NPs shared some absorption bands (Fig. 3C), such as those existing at 765 cm− 1, 1190 cm− 1, and 1320 cm− 1, which may correspond to the C-H group, the C = O group, and aromatic ring of LV, respectively41.
IR spectra, in the 400–4000 cm− 1 range, of PDA NPs, 5FU, 5FU@PDA NPs (A), CPT11, CPT11@PDA NPs (B), LV, and LV@PDA NPs (C).
Analysis of the interaction between PDA pyrocatechol, 5FU, CPT11, LV and CTX by ITC
Once 5FU, CPT11, LV, and CTX loading on PDA NPs was verified by FT-IR experiments, the interaction between the different compounds and the nanocarrier was analyzed by ITC. Nonetheless, assays were not carried out directly with the NPs, since PDA molecular weight is not accurately known. Instead, ITC assays were done with pyrocatechol, one primary monomer that is produced during DA oxidative polymerization, and which is responsible for PDA’s ability to load numerous compounds (drugs, peptides, proteins…)42,43,44. In this way, a concentration of monomer like that of PDA NPs employed was used to adsorb FOLFIRI compounds and CTX. Heat changes were detected when all drugs and the antibody interacted with pyrocatechol, and binding isotherms were built and fitted using an independent binding model (Figure S1). The calculated thermodynamic and binding parameters, including the association constants (Ka), the binding enthalpies (ΔH°), the binding entropies (ΔS°), and the binding free energies (ΔG°), can be seen in Table 1. According to the data obtained, it was verified that 5FU, CPT11, LV, and CTX interactions with pyrocatechol exhibited an exothermic behavior and were thermodynamically favorable. In general, there was a negative change of enthalpy and a positive change of entropy that favored such interactions, and the Ka values that were obtained may suggest that these bindings were electrostatic in nature. Besides, Ka value for CTX-pyrocatechol interaction was higher than for the rest of interactions, which could explain its slightly more negative ΔG° value45,46.
pH-responsive release of 5FU, CPT11, and LV from PDA NPs
Next, before performing cellular assays, the release rate of 5FU, CPT11, and LV from PDA NPs was evaluated in PBS at pH 4.85 and 7.40 to simulate lysosomal and physiological conditions, respectively. The drug release profiles, evaluated for 72 h, are depicted in Fig. 4. When analyzing the two graphs in that figure, it can be observed that, in general, the release of the three compounds displayed a burst-like pattern during the first hours, and that it was a little faster at acidic pH. More specifically and regarding 5FU, it should be noted that about 70% 5FU was released after 5 h in the acidic medium, while this release was somewhat less marked (54%) at the physiological pH after the same time. However, after 24 h, 5FU release profile at both pH values became more equal and, after 72 h, the amount of drug released in both media was similar and close to 95%. Regarding the release profile of CPT11, it was like that of 5FU. During the first 3 h of the assay, about 10% more drug was released at acidic pH than at the physiological pH but, after 5 h, CPT11 release was similar in both buffers, reaching values of 64–69% after 72 h. Finally, LV release also occurred more rapidly at acidic pH during the first hours of the experiment. Nevertheless, at the end of the assay, when the differences between both buffers were not so marked, the release of this compound was considerably lower than that of the two previous cytotoxic agents, reaching 44–53% after 72 h.
Globally, the release of greater percentages of drug at pH 4.85 may be attributed to the protonation of PDA amino groups in acidic environments, which could account for facilitating drugs’ release when NPs are endocyted in cells compared to physiological conditions47.
Drug release profile of 5FU (red), CPT11 (blue), and LV (green) at pH 4.85 (A) and 7.40 (B). The three compounds were simultaneously loaded on PDA NPs.
Otherwise, to study what mechanism could contribute to 5FU, CPT11, and LV release from PDA NPs under physiological conditions (diffusion, erosion, or swelling), four different mathematical models were implemented to evaluate the release kinetics of the drugs: zero-order, first-order, Higuchi and Korsmeyer-Peppas models. According to the results obtained, which can be found in the Supplementary Information along with the equations of the different models applied (Table S3), the Korsmeyer-Peppas model was found to be the best fitted to the drug release data, supported by the highest correlation coefficient (R2) values. In obedience to this model, the values of k, which is the release rate constant, were higher at pH 4.85, which could be explained by the fact that drug release took place faster at acidic pH. On the other hand, n is the diffusional exponent characteristic of the release mechanism and, as described in the literature, if it acquires values < 0.43, it will correspond to Fickian diffusion mechanisms, which may consequently govern the release of the FOLFIRI compounds from PDA NPs48,49,50.
Rapid cellular uptake of FOLFIRI-CTX@PDA NPs
Before accomplishing cytotoxicity studies, internalization of FOLFIRI-CTX-A488@PDA NPs in EGFR-overexpressing CRC cells was visualized under CLSM. Both HTC116 and HT29 human cell lines were used for this assessment51,52. As can be seen in Fig. 5, cellular uptake took place fast, since most NPs were distributed in the cellular perinuclear region after 30 min of incubation. Then, after 6 h of incubation, FOLFIRI-CTX-A488@PDA NPs could already be seen in the cytoplasm of the cells, especially in the HT29 cell line. In the HTC116 one, the complete internalization of the NPs, however, was much clear after 24 h. In any case, despite the anionic nature of their zeta potential, FOLFIRI-CTX-A488 NPs demonstrated excellent internalization, which is a fundamental characteristic that DDSs must have53,54. Possibly, thanks to the presence of the anti-EGFR antibody in the nanosystem, its internalization was propitiated by a receptor-mediated endocytosis process55.
FOLFIRI-CTX-A488@PDA NP uptake examined by CLSM in HTC116 and HT29 cells after 0.5, 6 and 24 h of incubation. Cells were treated with 30 (:{upmu:})g/ml FOLFIRI-CTX-A488@PDA NPs and stained with CellTracker™ Deep Red.
Cytotoxicity of PDA NPs loaded with the different FOLFIRI compounds and the anti-EGFR mAb
As for uptake experiments, HTC116 and HT29 CRC cells were used to assess FOLFIRI-CTX@PDA NP therapeutic efficacy in vitro. Thus, both human carcinoma cell lines were treated for 72 h with concentrations of this nanosystem ranging from 10 to 50 (:{upmu:})g/ml. Furthermore, they were also treated with the same concentrations of bare PDA NPs, PDA NPs loaded with one of the compounds (5FU@PDA NPs, CPT11@PDA NPs, LV@PDA NPs, and CTX@PDA NPs), and PDA NPs loaded simultaneously with the three drugs (FOLFIRI@PDA NPs) to make appropriate comparisons. All the results obtained can be seen in the Supplementary Information (Figures S2-S4). In the manuscript, with the aim of summarizing the results, only those corresponding to the assays that were performed treating HTC116 and HT29 cells with 30 (:{upmu:})g/ml of the different PDA NPs can be found (Fig. 6A-B).
According to them, bare PDA NPs were able to reduce the viability of both tumor cells by more than 30% after 72 h, highlighting what had already been reported in several previous works23,56,57. Besides, LV@PDA NPs and CTX@PDA NPs had similar cytotoxic effect to PDA NPs, which could lead to the assumption that the concentrations of LV and the anti-EGFR antibody incorporated in PDA NPs did not have significant effect on CRC cell viability. On the contrary, those that had more marked cytotoxic effect were the NPs loaded with 5FU or CPT11, which, after 72 h of treatment, managed to reduce tumor cell viability by 50–60%. Moreover, it should be noted that 5FU@PDA NPs action was more remarkable during the first 24 h, possibly because, according to the release assays, 5FU was released quicklier from PDA NPs than CPT11. Finally, as can be noted in Fig. 6A-B, co-loading PDA NPs with 5FU, CPT11, and LV significantly contribute to augment their cytotoxicity, especially if the anti-EGFR mAb was also incorporated. In this manner, FOLFIRI@PDA NPs and FOLFIRI-CTX@PDA NPs managed to reduce the survival rate of HTC116 cells to 24% and 22% after 72 h, while they decreased HT29 viability rate to 33 and 30%, respectively. Thus, synergy among all the drugs, the antibody, and the PDA-based nanocarrier was evident.
Viability reduction (%) of (A) HTC116, (B) HT29 (B), and (C) HS5 cells caused by the different PDA-based nanosystems synthesized (30 (:{upmu:})g/ml). Each assay was repeated thrice, and p-values were obtained by comparing the cytotoxic effect of the different nanosystems with that of bare PDA NPs after 72 h.
On the other hand, in addition to studying the cytotoxicity of the different PDA-nanosystems for CRC cells, viability assays were also carried out with healthy stromal cells, which were treated with the same NP concentrations as tumor cells. In this case, as can be noted in Fig. 6C, all the synthesized NPs exhibited much lower cytotoxicity. Firstly, the intrinsic antiproliferative effect of bare PDA NPs was significantly smaller, only reducing the viability of stromal cells by 20% after 72 h. After this time, CTX@PDA NPs also reduced the viability of healthy cells by about 20%, while LV@PDA NPs did so by 30%, significant lower percentages than for CRC cell lines. Likewise, after 72 h days, 5FU@PDA NPs and CPT11@PDA NPs decreased stromal cell viability by 35%, while this reduction had been 50–55% for malignant cells. Also, FOLFIRI@PDA NPs and FOLFIRI-CTX@PDA NPs reduced HS5 cell viability 20% less than the viability of HTC116 and HT29 cells. Thereby, the lower toxicity of the nanosystems for healthy cells than for tumor cells was noticeable, a very relevant fact that could contribute to reduce the side effects of the carried drugs in the future.
Therapeutic efficacy of FOLFIRI-CTX@PDA NPs in EGFR-overexpressing MCTS
Given that 2D cell cultures often have limitations, it was decided to finish this work by studying the therapeutic efficacy of the developed nanosystem also in 3D cell cultures, since they better mimic tumor clinical behavior58. MCTS were developed from HTC116 and HT29 cells and, when they were incubated with PDA NPs and FOLFIRI-CTX@PDA NPs for 72 h, alterations appeared in their morphology. Firstly, it should be noted that bare PDA NPs, despite not having very marked effect, could reduce by themselves the size of both types of spheroids and could reduce their degree of compaction, as can be seen in Fig. 7 and S5. Thus, PDA NP intrinsic anticancer activity was also evident in 3D cell cultures. Otherwise, FOLFIRI-CTX@PDA NP therapeutic effect was very significant, since they managed to considerably diminish the size of the MCTS, which exhibited much less spherical shape after the elimination of the tumor cells that surrounded their necrotic core (Fig. 7). In this way, FOLFIRI-CTX@PDA NPs, by maintaining their effectiveness in these 3D models that better mimic the effect of the tumor microenvironment on drug response, could be an excellent candidate for carrying out in vivo assays in a near future.
CLSM images of HTC116 and HT29 MCTS incubated with 30 (:{upmu:})g/ml PDA NPs and FOLFIRI-CTX@PDA NPs for 72 h. Alive cells were stained with calcein AM (green) and, dead ones, with PI (red).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41598-024-80879-0